EIC- Transition – iCURE - Innate Immune system activation to cure resistant bacterial infections
| Reference number | |
| Coordinator | Inicure AB |
| Funding from Vinnova | SEK 485 000 |
| Project duration | April 2025 - September 2025 |
| Status | Ongoing |
| Venture | Global cooperation 2025 |
| Call | Planning grant for international proposal 2025 |
Purpose and goal
Inicure in collaboration with researchers in the US and UK has developed a new immune-activating therapy to combat resistant infections. Inicure´s patented compounds have strong anti-infective properties with great potential for the treatment of antibiotic-resistant wounds and acute life-threatening resistant infections. The project aims to improve our EIC-Transition proposal and obtain funding to develop small molecule therapies to treat antimicrobial resistance (AMR).
Expected effects and result
Improving EIC Transition-ansökan (iCURE) from 2024 which did not reach the funding threshold due to very high competition. 1. Medicinal chemistry maturity 2. Preklinisk POC-validering 3. Market strategy The planning project will strengthen our IPR, business plan and regulatory strategies and completed preclinical POC pilot studies as well as initiated industrial partnerships will strengthen our EIC-Transition-ansökan with a budget of 2.5M€.
Planned approach and implementation
1. Medicinal Chemistry Maturity Optimization of our drug candidates with support by SciLifeLab, to raise the level of technical development. 2. Preklinisk POC-validering Effektstudier to characterize mechanisms of action in relevant infection models. 3. Market Strategy Develop business strategy, patent position, regulatory plan and establish research agreements with research institutes, pharmaceutical partners, and investors